Platelet–Leukocyte Hybrid Membrane‐Coated Immunomagnetic Beads for Highly Efficient and Highly Specific Isolation of Circulating Tumor Cells

• Published in: Advanced functional materials Vol. 28; no. 34
• Main Authors: Rao, Lang, Meng, Qian‐Fang, Huang, Qinqin, Wang, Zixiang, Yu, Guang‐Tao, Li, Andrew, Ma, Weijie, Zhang, Nangang, Guo, Shi‐Shang, Zhao, Xing‐Zhong, Liu, Kan, Yuan, Yufeng, Liu, Wei
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc 22.08.2018
• Subjects: Antibodies; Beads; Biomedical materials; Biomimetics; Blood circulation; Cancer; cancer early diagnosis; Cell membranes; cell sequencing; circulating tumor cells; Coating; Homology; hybrid cell membrane coatings; Leukocytes; liquid biopsy; Materials science; Membranes; Mutation; Nanoparticles; Tumors
• ISSN: 1616-301X; 1616-3028
• DOI: 10.1002/adfm.201803531

Biomimetic cell‐membrane‐camouflaged nanoparticles with desirable features have been widely used for various biomedical applications. However, the current research focuses on single cell membrane coating and using multiple cell membranes for nanoparticle functionalization is still challenging. In this work, platelet (PLT) and leukocyte (WBC) membranes are fused, PLT–WBC hybrid membranes are coated onto magnetic beads, and then their surface is modified with specific antibodies. The resulting PLT–WBC hybrid membrane‐coated immunomagnetic beads (HM‐IMBs) inherit enhanced cancer cell binding ability from PLTs and reduce homologous WBC interaction from WBCs, and are further used for highly efficient and highly specific isolation of circulating tumor cells (CTCs). By using spiked blood samples, it is found that, compared with commercial IMBs, the cell separation efficiency of HM‐IMBs is improved to 91.77% from 66.68% and the cell purity is improved to 96.98% from 66.53%. Furthermore, by using the HM‐IMBs, highly pure CTCs are successfully identified in 19 out of 20 clinical blood samples collected from breast cancer patients. Finally, the robustness of HM‐IMBs is verified in downstream CTC analysis such as the detection of PIK3CA gene mutations. It is anticipated that this novel hybrid membrane coating strategy will open new possibilities for overcoming the limitations of current theranostic platforms. Biomimetic platelet–leukocyte hybrid membrane‐coated immunomagnetic beads with enhanced cancer binding and reduced leukocyte interaction are used for ultrahigh‐efficiency and ‐purity isolation of circulating tumor cells from the blood samples of cancer patient. The combination of biomimetic hybrid cell membrane coating and immunomagnetic beads embodies a novel materials design strategy and presents a compelling class of advanced functional materials.